Melbourn promotes Derek Solomon

Moves from laboratory manager to operations director

Melbourn Scientific, a UK provider of analytical and formulation contract research services for the pharma and biotech industries, is broadening its management team with the promotion of laboratory manager Derek Solomon to the new role of operations director.

Solomon joined Melbourn Scientific in 2005 and has overseen the expansion of the services portfolio, which included the recent addition of clinical manufacture to its formulation development services.

You may also like

Research & Development

Intertek acquires Melbourn Scientific

Combines advanced capabilities for measuring device/drug interaction with OINDP drug characterisation expertise
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

A finite resource: helium

Although helium may be the second most abundant element in the universe, here on earth this noble gas is rare and precious. In the pharmaceutical industry helium is used for cryogenic cooling of magnets used for MRI and in gas chromatography
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Research & Development

Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial

BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.
Subscribe now